Biotech

All Articles

AstraZeneca pays CSPC $100M for preclinical heart disease medication

.AstraZeneca has settled CSPC Drug Team $100 thousand for a preclinical heart attack drug. The deal,...

Zephyrm finds Hong Kong IPO to finance phase 3 tissue therapy tests

.Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankr...

Frazier Lifestyle Sciences gathers $630M for small, mid-cap biotechs

.Frazier Life Sciences has sourced an even more $630 million for its fund paid attention to tiny as ...

GigaGen gathers as much as $135M BARDA bucks to beat botulism

.Antitoxin aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its...

GPCR agency Septerna files for IPO on toughness of preclinical information

.Septerna will learn how a biotech without "any type of purposeful scientific information" meals in ...

Kurma closes first $154M haul for most significant biotech fund as yet

.International VC agency Kurma Allies has introduced its own most up-to-date biotech fund, along wit...

Prothena markets one officer while yet another keeps-- Chutes &amp Ladders

.Accept to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, firings an...

Editas profit Tip Cas9 licensing civil rights for $57M

.Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medication is actually mon...

Ultragenyx modifies gene treatment application to dial up effectiveness

.A minority of individuals taking Ultragenyx Pharmaceutical's Wilson ailment genetics treatment UX70...

Biopharma discharge cost supports in Q3: Tough Biotech study

.As summertime warmth counts on cool winds, really hopes that this year will bring common field comf...